Table 4 Changes from baseline in secondary efficacy endpoints over Weeks 1–24 (intent-to-treat population)
FF 100 μg | FF 200 μg | |
|---|---|---|
(N = 108) | (N = 111) | |
Percentage of rescue-free 24-hour periods (Weeks 1–24) | ||
n | 108 | 109 |
Baseline | 14.3 | 11.5 |
LS mean change from baseline (SE) | 21.3 (3.05) | 23.1 (3.03) |
Treatment difference vs. FF 100 μg (95% CI) | NA | 1.8 |
(-6.7, 10.3) | ||
Percentage of symptom-free 24-hour periods (Weeks 1–24) | ||
n | 108 | 109 |
Baseline | 6.1 | 4.9 |
LS mean change from baseline (SE) | 17.5 (2.80) | 19.6 (2.79) |
Treatment difference vs. FF 100 μg (95% CI) | NA | 2.1 |
(-5.7, 9.9) | ||
PM peak expiratory flow (L/min) (Weeks 1–24) | ||
n | 108 | 109 |
LS mean | 342.7 | 344.0 |
LS mean change from baseline (SE) | 5.9 (3.26) | 7.2 (3.25) |
Treatment difference vs. FF 100 μg (95% CI) | NA | 1.3 |
(-7.8, 10.4) | ||
AM peak expiratory flow (L/min) (Weeks 1–24) | ||
n | 108 | 109 |
LS mean | 340.8 | 340.6 |
LS mean change from baseline (SE) | 13.4 (3.22) | 13.2 (3.20) |
Treatment difference vs. FF 100 μg (95% CI) | NA | -0.2 |
(-9.2, 8.8) | ||